🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Upcoming biologic patent expiries are spread across 13 broad therapeutic areas. However, the #biosimilar pipeline does not reflect this diversity. Addressing the #biosimilarvoid means driving massive savings for patients undergoing treatment for serious medical conditions –

In 2023, #generics & #biosimilars saved America’s patients & the U.S. healthcare system $445B, an increase of $37B in savings from the previous year. Learn more—including what can be done to help safeguard this important industry: accessiblemeds.org/resources/blog… #GRxBiosimsSavingsReport

Congratulations are in order today, as our #AAM president & CEO John Murphy III has earned well-deserved recognition on Washingtonian 🌸’s 2025 list of ‘The 500 Most Influential People Shaping Policy.’ washingtonian.com/2025/05/07/was…

Register now for early bird rates - available until July 11, 2025. GRx+Biosims™ 2025 is the must-attend conference for regulatory science and policy professionals in the U.S. #generics and #biosimilars industry! This event delivers timely updates from the FDA, opportunities for

Register now for early bird rates - available until July 11, 2025. GRx+Biosims™ 2025 is the must-attend conference for regulatory science and policy professionals in the U.S. #generics and #biosimilars industry! This event delivers timely updates from the FDA, opportunities for

Biosimilars saved patients & the U.S. healthcare system $12.4 billion in 2023. Imagine the additional savings that would come from legislative and regulatory actions aimed to support new biosimilar adoption! Learn more in our 2024 #GRxBiosimsSavingsReport: accessiblemeds.org/resources/blog…

New analysis from @IQVIA_Institutereveals a dangerous #biosimilarvoid: a staggering 90% of biologic drugs losing patent exclusivity over the next ten years have no #biosimilar competition in the pipeline. The health of millions of Americans depends on policymakers taking action

Since the first #biosimilar launch in 2015, patients and the U.S. healthcare system have saved nearly $36 billion. Additionally, biosimilars have been used in almost three billion days of patient therapy. However, regulatory and market barriers to entry are slowing biosimilar

“Ironically, the legislation intended to impose price controls on high-priced brand-drugs could have the perverse effect of extending the very brand-drug monopolies it sought to end. The choice is simple: empower competition, or risk losing it.” Read more in the Council’s

Since 2015, #biosimilars have saved ~$36B, but adoption is still low! PBM practices favoring high-priced biologics with rebates prevent access to cheaper biosimilars. Learn more: accessiblemeds.org/resources/blog… #GRxBiosimsSavingsReport

Will Drug Price Order Deliver on the Promise of Biosimilars? "Although biosimilars promise significant savings, practical obstacles have hindered their widespread adoption." dcjournal.com/will-drug-pric…

As the U.S. FDA has made clear, there is no clinically meaningful difference between biosimilars and interchangeable #biosimilars. Yet the U.S. remains the only country in the world with this additional, unnecessary designation – one that brand-name drug companies have exploited

We know the livelihood of America’s patients improves with access to lower-cost #biosimilar medicines – especially patients being treated for rare diseases where treatment options are limited and expensive. Unfortunately right now, we are stuck in the #biosimilarvoid.

#Biosimilar competition has given patients 495 million more days of therapy! To further increase access, policymakers must cut development costs and promote adoption. This will drive competition and lower prices. More in our #GRxBiosimsSavingsReport: accessiblemeds.org/resources/blog…